Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.45M fell 14.9% year over year, ahead of the -39.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.

Context

  • Stock-based compensation amounted to 9.5% of revenue in FY2025.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -14.9% holds above the trailing-twelve-month pace of -39.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.45M+2.5% QoQ
Last fiscal yearDec 2025
$6.63M-37.6% YoY
LTMMar 2026
$6.38M-39.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.9%——
1 year-37.6%——
3-year CAGR-18.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.63M USD
Year-over-year change
-37.6%
4-year CAGR
-17.1%

Stock-Based Compensation vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.9% is the 10th highest of 11, against a peer median of +20.3%.
  • Over three fiscal years its annual growth of -18.4% compares with a peer median of +20.1%.
BDTX Competitors
Stock-Based Compensation for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M USD-32.9%-11.7%22.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M USD-28.1%+4.4%5116.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M USD-32.8%+2.7%99.6%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$8.33M USD+7.1%+52.3%57.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M USD+42.2%—26.1%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$6.38M USD-39.9%-18.4%—
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$6.24M USD+33.6%+18.6%12.2%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$2.64M USD+336.0%+112.4%—
IMRXImmuneering CorporationLTM Mar 2026$1.52M USD-69.5%——
Peer median (excluding BDTX) —+20.3%+20.1%78.4%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Depreciation & Amortization205K508K437K343K325K
Deferred Income Tax2.18M0000
Stock-Based Compensation14.04M12.2M9.6M10.63M6.63M
Change in Working Capital7.02M(9.9M)3.69M(2.69M)(8.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.57M(2.23M)597K1.68M(3.43M)
Other Working Capital5.45M(7.67M)3.09M(4.38M)(5.3M)
Other Non-Cash Items2.01M3.28M2M(905K)9.02M
Operating Cash Flow(100.15M)(85.08M)(66.72M)(62.3M)29.61M
Capital Expenditures(2.71M)(192K)(33K)00
Acquisitions (Net)2.7M9K094K27K
Purchases of Investments(49.51M)(60.14M)(61.89M)(122.88M)(164.03M)
Sales of Investments182.83M113.69M78.17M139.75M119.02M
Other Investing Activities(2.7M)095K074K
Investing Cash Flow130.61M53.37M16.35M16.97M(44.91M)
Debt Repayment00000
Common Stock Issued729K177K71.85M24.49M(146K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0082K1.05M0
Financing Cash Flow729K177K71.93M25.55M(146K)
Effect of Forex Changes00000
Net Change in Cash31.19M(31.54M)21.56M(19.79M)(15.44M)
Free Cash Flow(102.86M)(85.27M)(66.75M)(62.3M)29.61M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.